P-162 Atezolizumab and bevacizumab pre-liver transplantation for patients with hepatocellular carcinoma beyond Milan criteria

Abstract

Hepatocellular carcinoma (HCC) represents the second most common cause of cancer-related death and accounts for over 80% of primary liver cancers worldwide. Curative treatment options include surgical resection in patients with well-compensated liver function and radiofrequency ablation in small tumors. However, in 90% of patients, HCC occurs in the setting of cirrhosis where optimal management remains liver transplantation (LT) with 5-year survival rates of approximately 80%. Atezolizumab is a humanized immunoglobulin Ig G1 monoclonal antibody that targets PD L1 and inhibits the interaction between PD-L1 and its receptors, PD-1 and B7-1 (CD80), both of which function as inhibitory receptors expressed on T cells.